Weekly VELCADE in Combination with Rituximab Improves Progression-Free Survival and Response Rate in Patients with Relapsed or Refractory Follicular Lymphoma - Drugs.com MedNews
Links shared publicly online about this topic.
- 667total visits
Weekly VELCADE in Combination with Rituximab Improves Progression-Free Survival and Response Rate in Patients with Relapsed or Refractory Follicular Lymphoma - Drugs.com MedNews
Addition of VELCADE increased progression-free survival by Dec 7, 2010 - Millennium The Takeda Oncology Company today reported the final results of a Phase III
View full resource at drugs.com
Tags: Lymphoma, Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma Medication, Rheumatoid Arthritis Medication, Drug, Rituxan, MabThera
Most Recently Shared on December 9, 2010 at 10:10 pm By:
Weekly VELCADE in Combination with Rituximab Improves Progression-Free Survival and Response Rate in Patie... http://bit.ly/hstb1b #drug
Advertisement
